DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer Pipeline Insights, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including ALK-positive Non-Small Cell Lung Cancer clinical trials and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the ALK-positive Non-Small Cell Lung Cancer Pipeline treatment landscape of the report, click here @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook
ALK-positive Non-Small Cell Lung Cancer Overview
ALK-positive lung cancer is a non-small cell lung cancer (NSCLC) that harbors a mutation in a gene called anaplastic lymphoma kinase (ALK). More precisely, it’s a gene rearrangement—a fusion of ALK and another gene, echinoderm microtubule-associated protein-like 4 (EML4). This abnormal fusion causes cell enzymes (proteins) to send signals to mutated cancer cells telling them to divide and multiply more quickly than usual, which spreads the disease.
Key takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
For further information, refer to the detailed ALK-positive Non-Small Cell Lung Cancer Unmet Needs, ALK-positive Non-Small Cell Lung Cancer Market Drivers, and ALK-positive Non-Small Cell Lung Cancer Market Barriers, click here for ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis
ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile
Ensartinib is a potential best-in-class compound for the first-line treatment of anaplastic lymphoma kinase (ALK)–positive non-small cell lung cancer (NSCLC). Ensartinib has shown promising clinical activity in patients with ALK-positive NSCLC in a phase 1/2 trial. A single-arm phase 2 trial of ensartinib as second-line treatment for patients with ALK-positive NSCLC previously treated with crizotinib has been completed in 156 Chinese patients, and a New Drug Application has been filed in China. An ensartinib global first-line phase 3 registration trial vs crizotinib is ongoing.
TQ-B3139 is an orally available, small molecule inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor (c-Met; HGFR), with potential antineoplastic activity. Upon oral administration, TQ-B3139 binds to and inhibits the activity of ALK and c-Met, which leads to the disruption of ALK- and c-Met-mediated signaling and the inhibition of cell growth in ALK- and c-Met-expressing tumor cells. ALK and c-Met, overexpressed or mutated in many tumor cell types, play key roles in tumor cell proliferation, survival, invasion and metastasis.
Request a sample and discover the recent advances in ALK-positive Non-Small Cell Lung Cancer Ongoing Clinical Trial Analysis and Medications, click here @ ALK-positive Non-Small Cell Lung Cancer Treatment Landscape
ALK-positive Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for ALK-positive Non-Small Cell Lung Cancer. The companies which have their ALK-positive Non-Small Cell Lung Cancer drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Betta Pharmaceuticals/Xcovery, Chia Tai Tianqing Pharmaceutical Group, Merck, Pfizer etc.
Dive deep into rich insights for drugs for ALK-positive Non-Small Cell Lung Cancer Pipeline, click here @ ALK-positive Non-Small Cell Lung Cancer Unmet Needs and Analyst Views
Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
Got Queries? Find out the related information on ALK-positive Non-Small Cell Lung Cancer Mergers and acquisitions, ALK-positive Non-Small Cell Lung Cancer Licensing Activities @ ALK-positive Non-Small Cell Lung Cancer Emerging Drugs, and Recent Trends
Table of Content
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services